Written Question·Department of Health and Social Care·UIN 83207
Abiraterone
Tabled: 17 October 2025
Answered: 28 October 2025
Question
Danny Beales
Labour — Uxbridge and South Ruislip
To ask the Secretary of State for Health and Social Care, whether NHS England has approved any drugs with a higher incremental cost-effectiveness ratio than abiraterone for high-risk, non-metastatic prostate cancer in the last five years.
Answer
Dr Zubir AhmedNHS England has not calculated the incremental cost-effectiveness ratio for any policy proposition because NHS England uses a relative prioritisation process for policy propositions that require funding in line with the published NHS England Specialised C...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 83207) →